NYSEAMERICAN:PLX - Protalix BioTherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 733.33 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.84
▲ +0.03 (3.70%)

This chart shows the closing price for PLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Protalix BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLX

Analyst Price Target is $7.00
▲ +733.33% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Protalix BioTherapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 733.33% upside from the last price of $0.84.

This chart shows the closing price for PLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Protalix BioTherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/3/2021HC WainwrightLower Price TargetBuy$11.00 ➝ $7.00
6/8/2020HC WainwrightBoost Price TargetBuy$3.00 ➝ $11.00
10/18/2019HC WainwrightSet Price TargetBuy$30.00
10/2/2019HC WainwrightReiterated RatingBuy$30.00
6/10/2019HC WainwrightReiterated RatingBuy$30.00
3/19/2019HC WainwrightSet Price TargetBuy$30.00
12/13/2018HC WainwrightSet Price TargetBuy$40.00
10/9/2018HC WainwrightSet Price TargetBuy$40.00
9/24/2018HC WainwrightReiterated RatingBuy$40.00
8/13/2018HC WainwrightSet Price TargetBuy$40.00
7/25/2018HC WainwrightSet Price TargetBuy$40.00
6/11/2018HC WainwrightSet Price TargetBuy$50.00
5/11/2018HC WainwrightSet Price TargetBuy$50.00
3/14/2018HC WainwrightSet Price TargetBuy$50.00
3/7/2018HC WainwrightSet Price TargetBuy$50.00
2/12/2018HC WainwrightSet Price TargetBuy$50.00
2/1/2018HC WainwrightReiterated RatingBuy$50.00
1/4/2018HC WainwrightSet Price TargetBuy$50.00
11/29/2017HC WainwrightSet Price TargetBuy$50.00
11/9/2017HC WainwrightReiterated RatingBuy$50.00
8/10/2017HC WainwrightSet Price TargetBuy$50.00
5/23/2017Rodman & RenshawReiterated RatingBuy$50.00
4/17/2017Rodman & RenshawBoost Price TargetBuy$40.00 ➝ $50.00
4/17/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$40.00 ➝ $50.00
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/23/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Protalix BioTherapeutics logo
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
Read More

Today's Range

Now: $0.84
Low: $0.82
High: $0.85

50 Day Range

MA: N/A

52 Week Range

Now: $0.84
Low: $0.79
High: $7.02

Volume

146,907 shs

Average Volume

347,760 shs

Market Capitalization

$38.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Protalix BioTherapeutics?

The following sell-side analysts have issued reports on Protalix BioTherapeutics in the last year: HC Wainwright.
View the latest analyst ratings for PLX.

What is the current price target for Protalix BioTherapeutics?

1 Wall Street analysts have set twelve-month price targets for Protalix BioTherapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 733.3%. HC Wainwright has the highest price target set, predicting PLX will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Protalix BioTherapeutics in the next year.
View the latest price targets for PLX.

What is the current consensus analyst rating for Protalix BioTherapeutics?

Protalix BioTherapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLX will outperform the market and that investors should add to their positions of Protalix BioTherapeutics.
View the latest ratings for PLX.

How do I contact Protalix BioTherapeutics' investor relations team?

Protalix BioTherapeutics' physical mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company's listed phone number is (201) 696-9345 and its investor relations email address is [email protected] The official website for Protalix BioTherapeutics is www.protalix.com.